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ABSTRACT
A dynamic phenotypic change contributes to the metastatic progression and drug 
resistance in malignant melanoma. Nevertheless, mechanisms for a phenotypic change 
have remained to be addressed. Here, we show that Met receptor expression changes 
in a cell-autonomous manner and can distinguish phenotypical differences in growth, 
as well as in metastatic and drug-resistant characteristics. In metastatic melanoma, 
the cells are composed of Met-low and Met-high populations. Met-low populations 
have stem-like gene expression profiles, are resistant to chemotherapeutic agents, 
and have shown abundant angiogenesis and rapid tumor growth in subcutaneous 
inoculation. Met-high populations have a differentiated phenotype, are relatively 
resistant to B-RAF inhibitor, and are highly metastatic to the lungs. Met plays a 
definitive role in lung metastasis because the lung metastasis of Met-high cells 
requires Met, and treatment of mice with the Met-containing exosomes from Met-
high cells facilitates lung metastasis by Met-low cells. Clonal cell fate analysis showed 
the hierarchical phenotypical changes from Met-low to Met-high populations. Met-low 
cells either showed self-renewal or changed into Met-high cells, whereas Met-high 
cells remained Met-high. Clonal transition from Met-low to Met-high cells accompanied 
changes in the gene expression profile, in tumor growth, and in metastasis that were 
similar to those in Met-high cells. These findings indicate that malignant melanoma has 
the ability to undergo phenotypic change by a cell-intrinsic/autonomous mechanism 
that can be characterized by Met expression.
INTRODUCTION
The incidence of malignant melanoma is increasing 
faster than that of other solid tumors [1]. The 5-year 
survival rate is less than 20% for distant-stage metastatic 
malignant melanoma [2], indicating that metastasis is the 
main factor in a poor outcome. In addition, the aggressive 
characteristics of malignant melanoma results in an 
innate and acquired resistance to chemotherapeutic and 
molecular-targeted drugs.
Autocrine and paracrine growth factors secreted 
within a tumor microenvironment participate in 
metastasis and drug resistance in malignant melanoma 
[3, 4]. In addition to extrinsic factors in the tumor 
microenvironment, tumorigenicity and malignant 
characteristics are regulated by the heterogeneity of 
tumor cells. Cancer stem-cell models have provided 
one explanation for the phenotypic and functional 
heterogeneity in several types of tumors. In malignant 
melanoma, however, phenotypic heterogeneity among 
tumorigenic melanoma cells from patients was reversible 
and not hierarchically organized [5, 6]. Melanoma cells 
characterized by the histone demethylase JARID1B 
are more competent in sustaining tumor growth 
compared with JARID1B-negative populations, whereas 
JARID1B expression is reversibly turned on and off [7]. 
Melanoma cells gain resistance to molecular-targeted 
agents in response to hypoxia [8]. Thus, adaptive 
phenotypic plasticity and cell-intrinsic heterogeneity are 
characteristics of malignant melanoma.
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Met/hepatocyte growth factor (HGF) receptor 
mediates tumor cell proliferation, survival, invasion, and 
metastasis [9–11]. Previous studies have indicated that 
Met promotes proliferation, survival, and metastasis in 
malignant melanoma [12–15]. Comprehensive analysis 
for drug resistance conferred by the interaction between 
tumor cells and stromal cells has shown that HGF secreted 
from stromal cells confers resistance/survival in tumor 
cells against molecular-targeted agents [3, 4]. Recent 
study has indicated that Met plays a role in premetastatic 
niche formation in B16-F10 highly metastatic melanoma 
[16], suggesting an involvement of Met in the phenotypic 
plasticity and heterogeneity of melanoma. Understanding 
of the mechanisms by which the malignant characteristics 
of melanoma cells are regulated by Met could promote 
an understanding of stage progression and plasticity, and, 
hence, the design of better therapeutic interventions.
In the present study, we found that there are different 
populations in metastatic melanoma cells, and these are 
characterized by different cell-surface Met expressions. 
Cells with Met-low and Met-high expressions have 
different profiles in gene expression, tumorigenicity, 
growth, and metastasis. Cell-surface Met expression was 
found to be in dynamic equilibrium and regulated by 
hierarchical and cell-autonomous changes between Met-
low and Met-high populations.
RESULTS
Stem cell- and differentiation-related gene 
expressions in Met-low and Met-high 
populations
The cell-surface Met expression in B16-F10 
melanoma cells analyzed by flow cytometer was 
heterogeneous, and the cells were composed of Met-low 
and Met-high populations (Figure 1A). We purified Met-
low and Met-high cells by cell sorting with > 95% purity 
(Figure 1A). Met mRNA levels were much higher in the 
Met-high cells than those in the Met-low cells (Figure 
1B), suggesting that the difference in cell-surface Met 
expression was mainly due to a difference in Met gene 
expression. Met protein levels were higher and Met was 
phosphorylated in the Met-high cells compared with those 
in Met-low cells (Figure 1C). Because both Met-low and 
Met-high cells did not produce detectable levels of HGF, 
the phosphorylation of Met in Met-high cells seemed to be 
HGF-independent. HGF stimulated Met phosphorylation 
in Met-low cells, but this stimulation was not clear in 
Met-high cells (Figure 1C), while HGF stimulated cell 
migration of both Met-low and Met-high cells (not shown), 
suggesting some portions of Met could be activated in a 
HGF-dependent manner in Met-high cells.
To characterize Met-low and Met-high populations, we 
analyzed gene expression profiles via microarray analysis. 
Genes differently expressed by more than 2-fold between 
Met-low and Met-high populations were selected: 886 
genes were higher in Met-low than in Met-high cells, while 
353 genes were higher in Met-high than in Met-low cells 
(Supplementary Tables S1, S2). Gene ontology enrichment 
analysis revealed different expressions of gene clusters 
between these populations. The gene expressions clustered 
as “negative regulation of cell differentiation,” “stem cell 
maintenance,” and “response to UV” were higher in Met-
low than in Met-high populations. In contrast, the gene 
expressions clustered as “pigmentation,” and “melanocyte 
differentiation” were higher in Met-high than in Met-low 
populations (Figure 2A, Supplementary Tables S3, S4). In 
agreement with this, Met-high cells were highly pigmented, 
whereas Met-low cells were scarcely pigmented (Figure 2B). 
Likewise, mRNA for Syntaxin-3, a key gene for pigmentation 
of melanosome [17], was expressed at a much higher level in 
Met-high cells than in Met-low cells (Figure 2B).
Among the gene clusters shown in Figure 2A, Kit, 
Snai2, and Sox9 are expressed in the progenitor cells of 
melanocytes [18, 19], and are expressed at a higher level 
in Met-low cells. Oca2 and Hps1 promotes melanogenesis 
via melanosome transport [20, 21], and these are expressed 
at a higher level in Met-high cells. Xpa and Brca2 play a 
role in nucleotide excision repair [22, 23], which suggests 
a DNA repair function in UV-sensitive unpigmented 
cells in Met-low populations. Collectively, these gene 
expression profiles indicate that Met-low are more 
melanoblastic, while Met-high are more differentiated to 
a certain extent.
We confirmed the expressions of several genes by 
quantitative RT-PCR (Figure 2C). The Kit genes play a 
critical role in the migration and survival of melanoblasts. 
Sox10, Pax3 and Mitf genes are key regulators of 
melanocyte development [19, 24], and regulate Met 
expression in melanocytes and melanoma cells [15, 25]. 
The expressions of Kit and Sox9 genes were higher in 
Met-low than in Met-high cells, whereas no significant 
difference was seen in the expressions of Mitf (Figure 2C), 
Sox10 and Pax3 genes (not shown). Consistently, the dual 
analysis of the cell surface Met and Kit indicated the cells 
were composed of two major populations characterized 
by Kit-high/Met-low and Kit-low/Met-high (Figure 2D).
Next, we addressed the sensitivity of Met-low and 
Met-high cells to the cytotoxic anticancer drugs cisplatin 
(DNA cross-linking drug) and dacarbazine (DNA 
alkylating drug), because xenobiotic transporters Abcb1 
and Abcg2 genes known to cause multi-drug resistance 
[26, 27] were higher in the Met-low population than in 
the Met-high population (Figure 2E). Unfractionated 
cells were cultured for either 3 or 7 days in the absence 
or presence of 10 μM cisplatin or 1 mM dacarbazine, 
and surviving cells were analyzed for cell-surface Met 
expression (Supplementary Figure S1A). In the presence 
of cisplatin, the Met-high population was clearly decreased 
and had largely disappeared after 7 days. The same 
result was obtained for cells cultured in the presence of 
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dacarbazine. The populations of dead cells and apoptotic 
cells increased following treatment with either cisplatin 
or dacarbazine, and the numbers were higher in Met-high 
cells than in Met-low cells (Supplementary Figure S1B). 
Thus, compared with Met-high cells, Met-low cells were 
more resistant to chemotherapeutic agents, and the higher 
expressions of Abcb1 and Abcg2 in Met-low cells could 
have participated in this resistance.
Higher angiogenic and growth properties in Met-
low populations
To examine the tumor characteristics of Met-low 
and Met-high cells in vivo, Met-low and Met-high cells 
obtained after cell sorting were inoculated in the left and 
right subcutaneous regions, respectively, per each of the 
C57BL/6 syngenic mice. Both Met-low and Met-high cells 
formed tumors at a rate of 100%, when subcutaneously 
inoculated at 100 cells/site (n = 4). However, Met-low 
cells formed tumors more efficiently than Met-high 
cells when subcutaneously inoculated at 10 cells/site 
(100% (11/11) in Met-low cells and 72.7% (8/11) in Met-
high cells). Tumors from Met-high cells were highly 
pigmented, while the tumors from Met-low cells were 
mostly non-pigmented with the exception of partially 
pigmented regions (Figure 3A). Immunohistochemical 
analysis of Met expression showed that Met expression 
levels were maintained in tumor tissues after 28 days post-
inoculation (Figure 3B). Tumor cells derived from Met-
low populations showed a low level of Met expression, 
while tumor cells derived from Met-high populations 
showed a high level of Met expression.
The tumor volume in the Met-low cells became 
much larger than in the Met-high cells 28 days post-
inoculation (Figure 3C), indicating a more rapid growth 
potential in Met-low than in Met-high cells. We noticed 
a higher expression of genes characterized as “blood 
vessel morphogenesis” and “regulation of angiogenesis” 
in Met-low cells than in Met-high cells (Figure 3D, 
Supplementary Table S3), and, therefore, we analyzed 
tumor-associated angiogenesis by immunohistochemical 
staining of CD31-positive endothelial cells and α-smooth 
Figure 1: Heterogeneous cell-surface Met receptor expression in B16-F10 melanoma. A. B16-F10 melanoma cells were 
stained with anti-Met-PE antibody and analyzed by flow cytometry. Left panel indicates cell-surface Met receptor expression of the 
unfractionated B16-F10 melanoma cells (parental). Boxes in the panel indicate gates used for cell sorting into Met-low or Met-high. Cell-
surface Met expressions of Met-low (middle) and Met-high (right) cells were re-analyzed after sorting. B. Expression of Met analyzed by 
quantitative RT-PCR. Following cell sorting, the cells were cultured for 3 days and subjected to quantitative RT-PCR analysis. Each value 
represents the mean ± SD. The assay was done in triplicate and substantially same results were obtained. C. Expression of Met and Met 
tyrosine phosphorylation. Following cell sorting, the cells were cultured for 2 weeks and subjected to immunoprecipitation and Western blot 
analysis. In independently performed experiment using another lot Met-low and Met-high cells, substantially the same results was obtained.
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muscle actin-positive pericytes. The vascular structures of 
the endothelial cells surrounded by pericytes are abundant 
in Met-low tumors, whereas the vascular structures of 
endothelial cells were poorly surrounded by pericytes in 
Met-high tumors (Figure 3E). The blood vessel density 
was higher in Met-low than in Met-high tumors (Figure 
3F), and the vascular areas surrounded by endothelial cells 
were much larger in Met-low than in Met-high tumors 
(Figure 3G) (P < 0.05, Mann-Whitney’s test). These 
results suggest that the formation of functional blood 
Figure 2: Different characteristics of Met-low and Met-high populations. A. Expression profiles of genes that functionally 
belong to “negative regulation of cell differentiation,” “stem cell maintenance,” “pigmentation,” and “response to UV.” The analysis was 
performed using RNA samples prepared from two independently prepared Met-low and Met-high cells. B. Appearance of parental, Met-low 
and Met-high cells (left), and expressions of Syntaxin-3 mRNA (right). C. Expression of Kit, Sox9, and Mitf mRNA. D. Dual analysis of 
Kit and Met by flow cytometry. Parental, Met-low, and Met-high cells were stained with anti-Met and anti-Kit antibodies and analyzed by 
flow cytometry. E. Expression of Abcb1 and Abcg2 mRNA. Gene expression profiles were analyzed by microarray analysis, and the data 
obtained by microarray analysis were deposited to the Gene Expression Omnibus and can be accessed by No. GSE69741. Expressions of 
Syntaxin-3, Kit, Sox9, Mitf, Abcb1, and Abcg2 mRNA were analyzed by RT-PCR. Each RT-PCR analysis were done in triplicate and each 
value represents the mean ± SD. The same RT-PCR analysis was independently performed twice and substantially the same results were 
obtained.
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vessels may be attributable to the higher growth potential 
of tumors from Met-low cells.
To know whether selective suppression of Met 
might influence tumor growth properties, Met-high cells 
were subjected to the stable expression of shRNA targeting 
Met (sh-Met) or non-targeting shRNA (Non-target). The 
knockdown of cell-surface Met expression was confirmed 
by flow cytometry (Supplementary Figure S2A). When 
Met-low and Met-high cells (Met-high, sh-Met or Non-
target) were inoculated in the left and right subcutaneous 
regions, respectively, Non-target, sh-Met, and Met-high 
cells all showed lower tumor growth than that in Met-low 
cells (Supplementary Figure S2B). These results indicate 
that a change in Met expression alone does not regulate 
the difference in the tumor growth properties between 
Met-low and Met-high cells.
Figure 3: Tumorigenicity and tumor growth of Met-low and Met-high cells subcutaneously implanted in syngenic mice. 
A. Appearances of tumors. Tumors developed from Met-low (left side) (n = 11/11) and Met-high (right side) (n = 8/11) cells in the same 
mouse are indicated in pairs. NT, no tumor. A scale bar, 10 mm. B. Histological appearance and Met expression in subcutaneous tumors. 
Arrowheads indicate pigmented cells. Scale bars, 50 μm in left and right panels; 200 μm in middle panels. C. Growth of tumors derived 
from Met-low (n = 11) and Met-high (n = 11) cells. In independently performed same experiment, substantially the same results were 
obtained. Each value represents the mean ± SD. **p < 0.01 by Student’s t-test. D. Expression profile of genes characteristic to “blood vessel 
morphogenesis” in Met-low and Met-high cells. E. Blood vessels in subcutaneous tumors, as evaluated by immunohistochemistry for CD31 
(green) and α-smooth muscle actin (α-SMA) (red). Arrowheads indicate vascular structures. Scale bars, 50 μm. F, G. Blood vessel density 
(F) and area of blood vessels (G). The blood vessel density and area were determined using immunohisotochemical data of individual 
tumors from Met-low (n = 5) or Met-high (n = 5) cells. The area for luminal structures closed by CD31-positive endothelial was measured 
by image analysis. *p < 0.05 by Student’s t-test. In independently performed same experiment, substantially the same results were obtained.
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Highly metastatic properties of Met-high 
populations to the lung
We next addressed whether Met-low and Met-high 
populations might show different metastatic potentials. 
Met-low and Met-high cells isolated after cell sorting 
were cultured for 3 weeks (or 6 weeks in the case of cells 
expressing shRNA, see below), then 105 cells per mouse 
were injected into the tail veins (n = 13–15 for each 
experimental group), and the incidences of metastasis to 
the lungs were analyzed 21 days later. The number of lung 
metastasis was much higher in Met-high cells (39.1 ± 31.4 
per mouse) than in Met-low cells (8.3 ± 10.2 per mouse) 
(Figures 4A, 4B) (P < 0.01, Tukey’s test). Histological 
analysis indicated that tumors from Met-low cells were 
not pigmented, whereas tumors from Met-high cells 
were highly pigmented (Figure 4C). The number of lung 
metastases was significantly suppressed in Met-high cells 
expressing sh-Met but not in Met-high cells expressing 
Non-target (Figure 4B). Thus, Met contributes to the lung 
metastasis of melanoma cells.
A previous study indicated that Met in exosomes 
released from B16-F10 melanoma cells induces a 
premetastatic niche formation in lungs, thereby facilitating 
lung metastasis of melanoma cells [16]. Therefore, we 
prepared exosomes and analyzed Met protein levels in 
exosomes derived from Met-low and Met-high cells. 
Exosomes obtained from Met-low and Met-high cells 
showed an average size of 110.3 and 112.9 nm in diameter, 
respectively (Supplementary Figure S3A). The zeta potential 
values for exosomes from Met-low and Met-high cells 
were −35.1 and −31.1 mV, respectively, suggesting slightly 
different electrostatic characteristics (Supplementary Figure 
S3B). In Western blot analysis, similar Rab5 protein levels 
indicated that similar amounts of exosomes were released 
from Met-low and Met-high cells (Figure 4D). In addition 
to the Met level, the levels of TRP2, HSP70, HSP90, and 
VLA4 were analyzed, because exosomes from subjects with 
advanced-stage malignant melanoma contained higher levels 
of these proteins [16]. The exosomes prepared from Met-
high cells contained much higher Met protein than those 
prepared from Met-low cells. TRP2 and HSP90 were found 
in larger amounts in the exosomes in Met-high cells than in 
Met-low cells. Furthermore, the number of lung metastases 
of Met-low cells was increased to 2.2-fold higher levels by 
the pretreatment of mice with exosomes derived from Met-
high cells (Figure 4D). These data strongly suggest that the 
Met in exosomes contributes to the lung metastatic potential 
of Met-high cells.
In addition to lung metastasis, we found that Met-
low and Met-high cells showed different metastatic 
potentials to organs other than the lungs (Figures 5A, 5B, 
Supplementary Table S5), though the overall absolute 
number of metastases was much smaller compared with 
lung metastasis. Met-low cells formed several metastases 
in the liver, kidney, and subcutaneous tissues (3.9 ± 2.2 
per mouse), whereas Met-high cells showed either no 
metastasis or only a small number of metastases in the 
liver and subcutaneous tissues (0.7 ± 1.3 per mouse). 
The metastases derived from Met-low cells were not 
pigmented, while metastases from Met-high cells were 
(Figure 5A). The number of metastases of Met-low cells 
was not significantly changed by shRNA expression 
targeting Met (Figure 5B, Supplementary Table S5). 
Thus, Met-low populations include a small number of 
subfractions, which have metastatic potential for organs 
other than the lungs. Taken together, these results indicate 
a clear difference between Met-low and Met-high cells 
with respect to organ tropism in metastasis and Met is 
functionally involved in highly metastatic potential to the 
lungs in Met-high cells.
Hierarchical phenotypical changes from Met-low 
into Met-high populations
Next, we addressed whether each population is in 
a static state or in dynamic equilibrium. Met-low and 
Met-high cells were sorted by flow cytometry, subjected 
to clonal growth from a single cell, and the cell-surface 
Met expressions were analyzed in each population 21 
days later (Figure 6, Supplementary Figure S4). The Met 
expression was divided into 3 groups according to the 
following categories (Figure 6A): “Met-low,” more than 
85% of the total cells show a fluorescent intensity of less 
than 300; “Met-high,” more than 85% of the total cells 
show a fluorescent intensity of more than 300; and, “Met-
dim,” intermediate cells between Met-low and Met-high.
Of the 11 clonal populations derived from Met-low 
single cells, 3 populations stayed in Met-low, 5 populations 
were changed to transitional, and 3 populations were 
changed to Met-high (Figure 6B, Supplementary Figure 
S4). In contrast, of the 11 clonal populations derived from 
Met-high cells, one population was changed to Met-dim, 
and 10 populations stayed in Met-high. Thus, the Met-low 
populations were composed of both self-renewing clones 
and clones changeable from Met-low to Met-high cells. 
In contrast, most of the Met-high populations were stable, 
and no clonal population was changed from Met-high to 
Met-low. These results indicate the hierarchical phenotypic 
changes from Met-low into Met-high populations.
We next addressed whether the hierarchical 
change in Met expression could be observed in human 
malignant melanoma cells. Met expression in A2058 
melanoma cells was relatively heterogeneous, and a re-
analysis of Met-low and Met-high cells after cell sorting 
indicated that Met-low and Met-high cells existed as 
different populations (Supplementary Figure S5A). These 
populations were subjected to clonal growth, and the 
cell-surface Met expression was analyzed 28 days later 
(Figure 6A, Supplementary Figure S5B). Among the 
12 clonal populations derived from Met-low cells, one 
clonal population stayed in Met-low, whereas 11 clonal 
populations changed to Met-dim or Met-high. In contrast, 
all 12 clonal populations derived from Met-high stayed 
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in Met-high. Thus, the hierarchical phenotypical changes 
from Met-low into Met-high populations were observed 
not only in B16-F10 mouse melanoma cells but also in 
A2058 human malignant melanoma cells.
A previous study indicated that HGF facilitates 
resistance to BRAF inhibitor in malignant melanoma cells 
with an oncogenic BRAF mutation [3, 4]. HGF enhanced 
the survival of A2058 cells harboring a mutant BRAF in 
the presence of BRAF inhibitor (vemurafenib) in both Met-
low and Met-high cells (Supplementary Figure S6A), and 
higher survival/resistance was seen in Met-high cells than 
in Met-low cells at varying concentrations of vemurafenib 
(Supplementary Figure S6B). The increases in dead and 
apoptotic cells by vemurafenib were larger in Met-low cells 
Figure 4: Lung metastasis of Met-low and Met-high cells injected into tail vein. A. Appearance of metastases in lungs. Scale 
bars, 5 mm. B. The number of metastases in lungs. Met-low (n = 15), Met-high (n = 15), and Met-high cells expressing non-target shRNA 
(Non-target) (n = 13) or Met-targeting shRNA (sh-Met) (n = 14) were used. **p < 0.01 and *p < 0.05 by Tukey’s test. In independently 
performed three sets of same experiments using a smaller number of animals (n = 2 - 6 for each experimental group), substantially the 
same results were obtained, and values were combined. C. Different pigmentation in metastatic tumors in the lung. Scale bars, 200 μm. D, 
Protein levels in exosomes derived from Met-low and Met-high cells. Protein levels were analyzed by Western blot and Rab5 was used as 
markers to indicate the amount of exosomes. Substantially same results were obtained in an independently performed experiment using 
independently prepared exosomes. E. The effect of Met-high cell-derived exosomes on metastasis of Met-low cells to the lung. Mice were 
injected with saline or Met-high cell-derived exosomes for three weeks. Met-low cells were injected two weeks after the treatment with 
exosomes and lung metastasis was analyzed three weeks post-inoculation. n = 6 in each experimental group. **p < 0.01 and *p < 0.05 by 
Tukey’s test.
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than those in Met-high cells (Supplementary Figure S6C). 
Thus, the higher Met activation status in Met-high cells than 
in Met-low cells facilitates resistance to BRAF inhibitor.
Finally, we examined whether clonal transition 
from Met-low to Met-high cells might be accompanied 
by a change in tumor characteristics. The Met-high cells 
that had clonally transitted and expanded from Met-
low cells (low→high) were subjected to analyses for a 
gene expression profile, tumor growth and metastasis. 
Microarray analysis indicated that the expression of 
the characteristic genes in the transitted cells showed a 
transitional profile or closer profile to that of Met-high 
cells than to Met-low cells (Figure 6C). In subcutaneous 
tumor growth assays, tumor growth in the transitted cells 
was much less than that in the Met-low cells (Figure 6D), 
which is consistent with tumor growth characteristics 
in Met-low and Met-high cells (Figure 3C). Following 
intravenous injection, the transitted cells and Met-high 
cells formed much larger numbers of lung metastases, 
compared with the Met-low cells (Figure 6E). Met-low 
cells formed several metastases in organs other than the 
lungs, whereas the transitted and Met-high cells formed 
no, or only a few, metastases in organs other than the lungs 
(Figure 6F, Supplementary Table S6). Thus, the clonal 
transition from Met-low to Met-high was accompanied 
with the changes in gene expression profiles, tumor 
growth, and metastasis.
DISCUSSION
Melanomas are highly heterogeneous tumors, but 
the mechanisms for a phenotypic change remained mostly 
unknown [28]. Analysis of patient-derived xenograft 
models have shown that phenotypical heterogeneity 
is reversible within advanced malignant melanoma 
cells [5, 6]. Consistently, we found that phenotypical 
heterogeneity characterized by Met expression level is 
dynamically changed in a cell-intrinsic manner. However, 
this phenotype change is hierarchical from Met-low to 
Met high populations. Considering the stem-like gene 
expression profiles in Met-low populations and the 
pigmented phenotype in Met-high populations, the cell-
intrinsic and hierarchical change from Met-low cells to 
Met-high cells could be driven by a program reflecting 
melanocyte development, and this might explain the 
phenotypic diversity of some cases of melanomas.
Previous studies have indicated that Met functions in 
cancer stem cells in several cancer cell types, such as colon 
cancer, prostate cancer, and glioblastoma [29–31]. HGF 
enhances the epithelial-mesenchymal transition [9–11]. 
SOX9 participates in the cancer stem cell state and maintains 
mesenchymal features in some cancers [32]. In the present 
study, we found that Met is rather expressed in melanoma 
cells characterized by more differentiated phenotypes such 
as pigmentation, lower Kit and Sox9 expression. This 
discrepancy may relate to the particular developmental 
characteristic of melanocytes, i.e., Met is not expressed in 
melanoblasts, while the Met expression is induced during 
melanocyte development by Mitf genes [15, 25].
The metastatic characteristics of Met-low and Met-
high melanomas differed in organotropism. Met-high 
cells metastasize mostly to the lungs, whereas Met-low 
cells metastasize to the liver, kidney, and other tissues. 
The low frequency of multi-organ metastasis of Met-low 
cells suggests that only a small population of Met-low 
cells can metastasize to multiple organs. Identification 
and characterization of theses cells could lend a better 
understanding of the multi-organ metastatic potential of 
melanomas. On the other hand, our results indicate that the 
highly metastatic potential of Met-high cells functionally 
required Met expression. Consistent with the previous report 
describing that exosome-packaged Met from B16-F10 
Figure 5: Metastasis of Met-low and Met-high cells to organs other than lungs. A. Appearance of metastases in the liver, 
kidney, and subcutaneous (Sc) tissue. Arrowheads indicate tumors. Scale bars, 5 mm. B. The number of metastases in various tissues except 
lungs. Met-low (n = 14), Met-high (n = 15), and Met-high cells expressing non-target shRNA (Non-target) (n = 12) or Met-targeting shRNA 
(sh-Met) (n = 12) were used.**p < 0.01 and *p < 0.05 by Tukey’s test. In independently performed three sets of same experiments using a 
smaller number of animals (n = 2 - 6 for each experimental group), substantially the same results were obtained, and values were combined.
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Figure 6: Clonal change in Met expression, gene expression profile, and tumor characteristics of Met-low and Met-
high populations. A. Representative histographical profiles defined as “Met-low,” “Met-dim,” or “Met-high.” The threshold value for 
fluorescence intensity for Met expression was set at 300, and the cells were divided into 3 groups: “Met-low,” more than 85% of the total 
cells show a fluorescent intensity of less than 300; “Met-high,” more than 85% of the total cells show a fluorescent intensity of more than 
300; and, “Met-dim,” intermediate cells between Met-low and Met-high. B. Change in Met expression during clonal expansion of B16-F10 
and A2058 cells. Met-low and Met-high cells were sorted by flow cytometry, individually subjected to the clonal growth from a single cell, 
and cell-surface Met expression was analyzed in each population 21 days (B16-F10) or 28 days (A2058) later. Eleven (B16-F10) or twelve 
(A2058) clonal cell populations derived from Met-low and Met-high cells were analyzed. Met-low or Met-high clonal cells were obtained 
by independently performed cell sorting in twice.
(Continued )
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Figure 6 (Continued ): C. Comparison of gene expression profiles between Met-low, Met-high, and the Met-high cells transitted from 
Met-low (low→high). Among three samples in Met-low or Met-high, the data for two samples (lane 1 and 2) were taken from the same data 
sets used in Figure 2A and 3D. D. Tumor growth. Tumor growth by Met-low cells (n = 6) and the transitted Met-high cells (Met-low→Met-
high) (n = 6). Met-low and transitted Met-high cells were inoculated in the same mouse in pairs. *p < 0.01 by Mann-Whitney’s test. E, F. 
Metastasis to the lungs (E) and organs other than the lungs (F). Met-low (n = 10), Met-high (n = 12), and the transitted Met-high (Met-
low→Met-high) (n = 12) cells were used. ***p < 0.0001 and **p < 0.01 by Tukey’s test. The experiment was independently performed for 
three times (n = 2 - 4 for each experimental groups), substantially similar results were obtained, and values were combined.
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melanoma forms a pre-metastatic niche in lungs [16], we 
found that exosomes derived from Met-high cells contained 
much higher levels of Met than those from Met-low cells 
(Figure 4D), and the number of lung metastases of Met-
low cells was increased by the pretreatment of mice with 
exosomes derived from Met-high cells (Figure 4E). These 
data strongly suggested that the Met in exosomes functionally 
contributed to the lung metastatic potential of Met-high cells.
Tumor-associated angiogenesis differs between 
Met-low and Met-high melanomas. Tumors from Met-
high cells developed vascular structures without pericytes. 
This might be explained by the low expression of platelet-
derived growth factor (PDGF) and angiopoietin-2 
(Angpt2), because the former facilitates the recruitment 
of pericytes and the latter induces sprouting angiogenesis 
[34, 35]. On the other hand, Met-low cells expressed 
proangiogenic factors at a higher level and tumors 
from Met-low cells developed more vascular networks 
surrounded by pericytes. This vascularization in Met-low 
tumors may function more normally and can support a 
larger growth potential of Met-low tumors. Instead, the 
vascular structures lacking pericytes in Met-high tumors 
may allow transendothelial movement of tumor cells, 
thereby facilitating intravasation/extravasation of tumor 
cells during metastatic colonization.
Malignant melanoma is one of the most 
chemoresistant tumors, and why melanomas are particularly 
insensitive to chemotherapeutic agents remains poorly 
understood [36, 37]. Xenobiotic transporters ABCB1 
(also known as MDR1 or P-glycoprotein) and ABCG2 
(also known as breast cancer resistance protein) plays a 
major role in drug resistance against chemotherapeutic 
agents [26, 27, 38, 39]. The higher expression levels of 
ABCB1 and ABCG2 in Met-low cells may explain, at 
least in part, why Met-low cell populations are more 
resistant to chemotherapeutic agents than Met-high cell 
populations. On the other hand, malignant melanoma 
harboring a mutant BRAF responds to RAF inhibitors, but 
the tumors often recur within a certain period of treatment 
[3, 39]. Expression of HGF and activation of Met confers 
resistance to BRAF inhibitors in patients [3, 4]. Met-high 
cell populations show a higher survival rate compared with 
Met-low cell populations in the presence of BRAF inhibitor 
(Supplementary Figure S6). Thus, Met-low and Met-high 
populations have shown resistance to chemotherapeutic 
and molecular-targeted agents in different ways, in 
which progenitor cell characteristics and Met activation 
participates in drug-resistance.
Finally, cell-intrinsic and hierarchical change in Met 
expression and the associated gene expression profiles could 
be a mechanism that might help explain the intrinsic diversity 
and plasticity in tumor growth, metastasis, and drug resistance 
in malignant melanomas. Elucidation of the mechanism by 
which Met expression in individual cells is regulated overall 
in a certain equilibrium between Met-low and Met-high 
cell populations may facilitate further understanding of the 
intrinsic nature of malignant melanomas.
MATERIALS AND METHODS
Cell culture, exosome preparation, shRNA 
expression, and reagents
Cells were obtained from the American Type 
Culture Collection. B16-F10 cells were cultured in 
RPMI1640 medium supplemented with 10% (v/v) fetal 
bovine serum. A2058 cells were cultured in DME medium 
supplemented with 10% (v/v) fetal bovine serum and 2 
mM glutamine. For analysis of Met expression in clonal 
cell populations, cells sorted by flow cytometry were first 
cultured on a 96-well plate at a density of one cell/well, 
and were then cultured for 3–4 weeks. Mouse Met shRNA 
sense sequences were obtained from the Broad Institute 
TRC shRNA library (Table 1). For exosome preparation, 
the culture supernatant was centrifuged at 500 × g for 
10 min, and filtered through a 0.22-μm filter membrane. 
The filtrate was centrifuged at 20,000 × g for 20 min, and 
exosomes were collected by centrifugation at 100,000 × 
g for 70 min. The particle size and the zeta potential of 
exosomes were analyzed using a ZETASIZER NANO 
(Malvern Instruments, Worcestershire, UK). Lentiviral 
vector encoding shRNA were prepared using HEK-293 
cells, and cells transfected with the lentiviral vector were 
cultured in the presence of 0.5–1.0 μg/ml puromycin for 
more than 7 days. Cisplatin and dacarbazine were obtained 
from WAKO Pure Chemicals. Vemurafenib and a BCA 
Protein Assay Kit were obtained from Selleckchem and 
Pierce Biotechnology, respectively.
Flow cytometry and antibodies
Cells were stained using either a rat anti-mouse Met-
PE antibody, a rat anti-human Met antibody (eBiosciences, 
code: 12-8854-82, clone eBioclone 7, or code: 14-
8858-80, clone eBioclone 97), or an anti-mouse Kit 
antibody (eBiosciences, code: 14-1172-81, clone ACK2). 
Secondary antibodies conjugated with phycoerythrin 
(PE) or allophycocyanin (APC) were used (Santa Cruz). 
Isotype controls were used to set the background. Live-
cell selection was accomplished using 7-AAD (BD 
biosciences). Cells were analyzed and/or sorted on a 
FACS canto II, a FACS Aria II (Becton Dickinson) or 
with a JSAN cell sorter (Bay Bioscience, Kobe, JAPAN). 
Cell cycles were determined using a Cell-Cycle Phase 
Determination Kit (Cayman Chemical, Ann Arbor, MI). 
Apoptotic cells were stained using an Annexin V-FITC 
Apoptosis Kit (BioVision, Milpitas, CA).
Microarray analysis
Microarray analyses were performed using the Whole 
Mouse Genome (4 × 44k, G4846A) Oligo Microarray, 
according to the Agilent 60-mer Oligo Microarray 
Processing Protocol (Agilent Technologies). Total RNA 
samples (200 ng) were used to prepare Cy3-labeled cRNA 
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using a Low RNA Input Fluorescent Linear Amplification 
Kit (Agilent Technologies). Fluorescence-labeled cRNAs 
were purified using an RNeasy RNA Purification Kit 
(Qiagen Inc., Hilden, Germany). Two independent RNA 
samples were used to confirm the reproducibility of the 
microarray analyses. The images were analyzed using 
Feature Extraction Software (Ver. 10.7.3.1) and GeneSpring 
GX 11.5 software (Agilent Technologies). Normalization 
was performed as follows: (i) intensity-dependent Lowess 
normalization; (ii) data transformation, with measurements 
set to ≤0.01; (iii) per-chip 75th-percentile normalization of 
each array; and, (iv) per-gene: normalized to the median 
of each gene. Genes differently expressed more than twice 
between Met-low and Met-high populations were selected 
and used for the gene ontology enrichment analysis. Gene 
ontology (GO) enrichment analyses were performed 
using DAVID Bioinformatics Resources 6.7. The raw and 
processed data were deposited in the Gene Expression 
Omnibus (GEO) database (access ID: GSE69741).
Tumor growth and metastasis assay
Five week-old female C57BL/6 mice (SLC, 
Shizuoka, Japan) were used. Met-low and Met-high 
cells were prepared via 2 successive cell sortings. For 
subcutaneous growth, 10, 50, or 100 cells in 50 μl culture 
medium were mixed with 50 μl of growth factor-reduced 
matrigel, and subcutaneously injected bilaterally. Tumor 
volume was analyzed on day 35 or within 35 days after 
the inoculation unless otherwise specified. For metastasis 
assay, 105 cells in 100 μl of PBS were injected into the 
tail veins, and the degrees of metastases were analyzed 
21 days later. All animal experiments were performed in 
accordance with the animal experiments guidelines of 
Kanazawa University.
Histological analysis
For immunostaining of Met, frozen sections were 
fixed with methanol, tissue sections were incubated with 
PBS containing 3% bovine serum albumin for 30 min, 
washed with PBS, and incubated overnight with rabbit 
anti-Met antibody (Santa Cruz, code: sc-162, clone SP-
260) in PBS containing 0.5% bovine serum albumin 
and 0.1% Tween-20 at 4 ˚C. After washing, sections 
were incubated with EnVision+ System-HRP Labeled 
Polymer (DAKO, code: K4002, Glostrup, Denmark). 
Immunocomplexes were visualized using an IMMPACT 
DAB kit (VECTOR, code: SK-4105, PE2 6XS, UK) and 
nuclei were stained with hematoxylin. For blood vessel 
staining, frozen sections were fixed with methanol, 
then treated with rat anti-CD31 (BD, code: 557355, 
clone MEC13.3) and mouse anti-α-smooth muscle actin 
(DAKO, code: M0851, clone 1A4, Glostrup, Denmark) 
antibodies were diluted via a Vector® M.O.M.™ 
Immunodetection Kit (Vector Laboratories, Burlingame, 
CA). Sections were analyzed using a Biozero BZ-9000 
(KEYENCE, Osaka, Japan).
Quantitative PCR
Total RNA was prepared using Sepasol RNA 
(Nacalai Tesque, Kyoto, Japan), and RNA were reverse 
transcribed using Superscript III Reverse Transcriptase 
and Oligo(dT) primer (Invitrogen). Quantitative PCR 
reactions were performed in triplicate using SYBR-
green dye (Roche Diagnostics) with the 7500 Sequence 
Detection System (Applied Biosystems, Streetsville, 
ON, Canada). The transcription level of β-actin was 
used for normalization. The primer sequences are listed 
in Table 2.
Table 1: Sense and antisense sequences for shRNA
Purpose Sense Anti sense
Non-target GCGCGATAGCGCTAATAATTT AAATTATTAGCGCTATCGCGC
sh-Met CGGGATTCTTTCCAAACACTT AAGTGTTTGGAAAGAATCCCG











Western blotting was performed as described 
elsewhere [40]. Briefly, a PVDF membrane was 
incubated with 5% bovine serum albumin for 2 h, and 
then incubated overnight at 4 ˚C with primary antibodies. 
After washing 3 times, the membrane was incubated 
for 1 h with species-specific horseradish peroxidase-
conjugated antibodies, and developed with ECL 
detection reagent (ImmunoStar, Wako Pure Chemical). 
For detection of Met tyrosine phosphorylation, cell 
lysate was subjected to immunoprecipitation with 
mouse anti-Met (code:#3127, clone 25H2) antibody 
(Cell Signaling Technology, Beverly, MA) and 
phospho-Met was detected using rabbit anti-phospho-
Met (Y1234/Y1235) (code:#3077, clone D26) antibody 
(1:1000 dilution, Cell Signaling Technology). Immune 
complexes were recovered with Protein G-Sepharose 
beads (Zymed Laboratories, South San Francisco, CA). 
For exosome analysis, antibodies against Met (25H2), 
Rab5 (rabbit, code:#5347, clone C8B1) (1:1000 dilution, 
Cell Signaling Technology), TRP2 (rabbit, code: 
BS3320, clone K89, 1:1000 dilution, Bioworld, Louis 
Park, MN), HSP70 and HSP90 (mouse, code: SPA-
810-D and ADI-SPA-830, clone C92F3A-5 and AC88, 
1:1000 dilution, Enzo Life Sciences, Farmingdale, NY), 
and VLA4 (rat, code: ab25247, clone PS/2, 1:1000 
dilution, Abcam, Cambridge, MA, USA) were used. Can 
Get Signal® (TOYOBO, Osaka, Japan) was used for the 
dilution of antibodies.
Statistical analysis
Error bars represent the means ± standard 
deviation. Mouse experiments were performed in 
duplicate using at least 4 mice per treatment group. 
Multiple-group comparisons were analyzed using either 
a Tukey’s test or ANOVA. Two group comparisons 
were analyzed using either a Student’s t-test or a Mann-
Whitney’s U test using Prism 6 software. A P < 0.05 was 
considered significant.
Abbreviations
HGF, hepatocyte growth factor; PE, phycoerythrin; 
GO, gene ontology; GEO, gene expression omnibus; 
ANOVA, analysis of variance; ABC, ATP-binding 
cassette.
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